Form 4: BioCryst Pharmaceuticals Director Steven K. Galson Reports Stock and Option Grants

Director Steven K. Galson reports acquisition of restricted stock units and stock options in BioCryst Pharmaceuticals.

Summary

• Steven K. Galson, a director of BioCryst Pharmaceuticals, reported transactions involving the company's stock.
• On June 12, 2024, Galson acquired 6,820 shares of common stock through an automatic non-employee director grant of Restricted Stock Units (RSUs) at a price of $0, which will vest on the first anniversary of the grant date.
• On the same date, Galson also acquired 49,933 stock options through an automatic non-employee director grant with an exercise price of $6.30, exercisable from June 12, 2025, and expiring on June 12, 2034.
• Galson directly owns 36,431 shares of common stock following the reported transactions.
• Additionally, Galson indirectly owns 21,940 shares through a trust where he is a trustee and the sole beneficiary with his family.
• A previous report incorrectly stated that Galson directly purchased shares on May 13, 2024; these shares were actually purchased by the trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard compensation practices and corrects a previous reporting error, indicating transparency. The grants align director interests with shareholders.

Positives

• The grant of RSUs and stock options to a director aligns their interests with the long-term success of the company.
• The vesting schedule of the RSUs encourages continued service by the director.
• The correction of the previous reporting error ensures accurate information is available to investors.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

This filing is a routine disclosure of stock and option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of directors with shareholders. These grants are typical for non-employee directors as part of their compensation package.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in the pharmaceutical industry.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize similar equity-based compensation for their board members.
• The size of the grant is typical for a company of BioCryst's size and market capitalization, aligning with industry benchmarks for director compensation.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term performance.
• The correction of the reporting error ensures that stakeholders have accurate information regarding the director's holdings.

Key Dates